GRC 54276 + pembrolizumab

GRC 54276 + pembrolizumab is an investigational combination therapy being studied for the treatment of advanced solid tumors and lymphomas. GRC 54276 is an orally available small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1), a negative regulator of T and B cell receptor signaling, developed by Glenmark. By inhibiting HPK1, GRC 54276 aims to enhance immune system activity against cancer cells. Pembrolizumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), approved for various cancers as an immune checkpoint inhibitor that blocks PD-1-mediated immunosuppression. The combination seeks to leverage both enhanced T-cell activation via HPK1 inhibition and checkpoint blockade via PD-1 inhibition to improve antitumor responses. Clinical trials are ongoing to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors or lymphomas who have progressed on standard therapies[4][7][8].